Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Overview:
Spinal muscular atrophy is a type of degenerative neurological disorder that affects the nervous system and the voluntary skeletal muscle. It is a common genetic disease characterized by muscular wasting in the motor nerves that are responsible for the movements. This disease can affect either one or more of the three main spinal cord sections. This disease is hereditary and typically begins in childhood and progresses through adulthood.
Growing awareness regarding rare disease and increasing initiatives to improve treatment options for SMA is projected to augment growth of the spinal muscular atrophy market. For example, the enactment of the Orphan Drug Act, 1983 in the U.S., and a similar act for orphan medicinal products in the EU has increased the importance of research activities for the management of rare diseases. Similarly, in 2017, the U.S. FDA approved an orphan drug license to RG7916, a joint development program by Roche, SMA Foundation, and PTC Therapeutics for the treatment of spinal muscular atrophy. Moreover, key players are heavily investing in R & D for the development of a curative treatment which is further anticipated to foster growth of the market.
North America is expected to gain significant growth over the forecast period and this is attributed to the increasing regulatory approval for the drug to treat spinal muscular atrophy in the region. For instance, in August 2020, the U.S. Food and Drug Administration approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease.
Key Developments:
- In July 2021, Roche has launched prescription medicine Evrysdi in India, which is used for the treatment of spinal muscular atrophy (SMA) in adults, children aged 2 months and older
- In May 2019, AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
- In August 2021, Chugai Pharmaceutical Co., Ltd. announced that it launched Evrysdi® Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA)
Key features of the study:
- This report provides in-depth analysis of spinal muscular atrophy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global spinal muscular atrophy market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
- Key companies covered as a part of this study include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the spinal muscular atrophy market
Detailed Segmentation:
Global Spinal Muscular Atrophy Market, By Disease Type:
Type I
Type II
Type III
Type IV
Global Spinal Muscular Atrophy Market, By Treatment:
Gene Therapy
Drugs
Global Spinal Muscular Atrophy Market, By Age:
Infant
Adult
Global Spinal Muscular Atrophy Market, By Geography:
North America
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
U.S.
Canada
Latin America
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
GCC
Israel
Rest of Middle East
Africa
By Disease Type:
Type I
Type II
Type III
Type IV
By Treatment:
Gene Therapy
Drugs
By Age:
Infant
Adult
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Biogen*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy
Cytokinetics, Inc.
F. Hoffmann-La Roche
Pfizer Inc.
Novartis AG
Ionis Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Disease Type
o Market Snippet, By Treatment
o Market Snippet, By Age
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Market Trends
o Pricing Analysis
o Clinical Trials For Spinal Muscular Atrophy
o Regulatory Landscape
o Reimbursement Scenario
o Pipeline Analysis
o Epidemiology
o PEST Analysis
4. Global Spinal Muscular Atrophy Market, By Disease Type, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Type I
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type II
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type III
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type IV
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
5. Global Spinal Muscular Atrophy Market, By Treatment, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Gene Therapy
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Drugs
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Age, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Infant
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Adult
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Region, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o U.S.
o Canada
o Latin America
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o GCC
o Israel
o Rest of Middle East
o Africa
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Biogen*
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Cytokinetics, Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o F. Hoffmann-La Roche
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Pfizer Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Novartis AG
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Ionis Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 32 market data tables and 26 figures on "Spinal Muscular Atrophy Market - Global forecast to 2026".
